The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Principles of antibacterial dosing in continuous renal replacement therapy
Abstract
OBJECTIVES: To outline the concepts involved in optimizing antibacterial dosing in critically ill patients with acute renal failure undergoing continuous renal replacement therapy (CRRT), provide a strategy for optimizing dosing, and summarize the data required to implement the strategy. DATA SOURCES: MEDLINE search from February 1986 to 2008. DATA EXTRACTION AND SYNTHESIS: Optimal dosing of antibacterials is dependent on achieving pharmacokinetic targets associated with maximal killing of bacteria and improved outcomes. The initial dose is dependent on the volume of distribution. Maintenance doses are dependent on clearance. Both should be adjusted according to the pharmacokinetic target associated with optimal bacterial killing, when known. The volume of distribution of some antibacterials is altered by critical illness or acute renal failure or both. Clearance by CRRT is dependent on the dose and mode of CRRT and the sieving or saturation coefficient of the drug. Both sieving and saturation coefficient are related to the plasma protein binding and thus may be altered in renal failure. CONCLUSIONS: Appropriate dose calculation requires knowledge of the pharmacokinetic target and the usual minimum inhibitory concentration of the suspected organism in the patient's locality (or if unavailable, the break point for the organism), published pharmacokinetic data (volume of distribution, non-CRRT clearance) on critically ill patients receiving CRRT (which may differ substantially from noncritically ill patients or those without renal failure), the sieving or saturation coefficient of the relevant drug in critically ill patients, the dose and mode of CRRT being used, and the actual dose of CRRT that is delivered. This large number of variables results in considerable inter- and intrapatient heterogeneity in dose requirements. This article provides basic principles and relevant data to guide the clinician in prescribing individualized dosing regimes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
Rangel-Frausto, M. S. (1995) · JAMA · doi:10.1001/jama.273.2.117 · Cited by 2,104
Pathogenetic Mechanisms of Septic Shock
Epstein, F. H., & Parrillo, J. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282008 · Cited by 1,548
Acute Renal Failure and Sepsis
Schrier, R. W., & Wang, W. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032401 · Cited by 1,260
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Septic Acute Kidney Injury in Critically Ill Patients: Clinical Characteristics and Outcomes
Bagshaw, S. M., Uchino, S., Bellomo, R., Morimatsu, H., Morgera, S., Schetz, M., Tan, I., Bouman, C., Macedo, E., Gibney, N., et al. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03681106 · Cited by 888
Calandra, T., & Cohen, J. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000168253.91200.83 · Cited by 839
Rybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
The systemic inflammatory response syndrome in acute liver failure
Rolando, N., Wade, J., Davalos, M., Wendon, J., Philpott-Howard, J., & Williams, R. (2000) · Hepatology · doi:10.1053/jhep.2000.17687 · Cited by 729
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720
Early acute kidney injury and sepsis: a multicentre evaluation
Bagshaw, S. M., George, C., Bellomo, R., & the ANZICS Database Management Committee (2008) · Critical Care · doi:10.1186/cc6863 · Cited by 685
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Aminoglycoside-Induced Ototoxicity
Selimoglu, E. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207779313731 · Cited by 446
Rybak, M. J., Abate, B. J., Kang, S. L., Ruffing, M. J., Lerner, S. A., & Drusano, G. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1549 · Cited by 431
Ciprofloxacin: An Updated Review of its Pharmacology, Therapeutic Efficacy and Tolerability
Davis, R., Markham, A., & Balfour, J. A. (1996) · Drugs · doi:10.2165/00003495-199651060-00010 · Cited by 389
Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380
Song, J.-H., Jung, S.-I., Ko, K. S., Kim, N. Y., Son, J. S., Chang, H.-H., Ki, H. K., Oh, W. S., Suh, J. Y., Peck, K. R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2101-2107.2004 · Cited by 359
Prevention of Resistance: A Goal for Dose Selection for Antimicrobial Agents
Drusano, G. L. (2003) · Clinical Infectious Diseases · doi:10.1086/344653 · Cited by 356
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
An overview of drug-induced acute kidney injury
Pannu, N., & Nadim, M. K. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318168e375 · Cited by 352
Once versus thrice daily gentamicin in patients with serious infections
Prins, J. M., Buller, H. R., Speelman, P., Kuijper, E. J., & Tange, R. A. (1993) · The Lancet · doi:10.1016/0140-6736(93)90137-6 · Cited by 350
DENNESEN, P. J. W., van der VEN, A. J. A. M., KESSELS, A. G. H., RAMSAY, G., & BONTEN, M. J. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.6.2007020 · Cited by 340
Antibiotic resistance—What’s dosing got to do with it?
Roberts, J. A., Kruger, P., Paterson, D. L., & Lipman, J. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318180fe62 · Cited by 339
Self-citationPea, F., Viale, P., & Furlanut, M. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00002 · Cited by 327
Kinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy
Trotman, R. L., Williamson, J. C., Shoemaker, D. M., & Salzer, W. L. (2005) · Clinical Infectious Diseases · doi:10.1086/444500 · Cited by 292
Roberts, J. A., & Lipman, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645080-00001 · Cited by 283
Self-citationIn Vivo Pharmacodynamics of a New Oxazolidinone (Linezolid)
Andes, D., van Ogtrop, M. L., Peng, J., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3484-3489.2002 · Cited by 278
Ricci, Z., Ronco, C., D'amico, G., De Felice, R., Rossi, S., Bolgan, I., Bonello, M., Zamperetti, N., Petras, D., Salvatori, G., et al. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi296 · Cited by 274
Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally
Eliopoulos, G. M., Drusano, G. L., Ambrose, P. G., Bhavnani, S. M., Bertino, J. S., Nafziger, A. N., & Louie, A. (2007) · Clinical Infectious Diseases · doi:10.1086/520991 · Cited by 266
Brunet, S., Leblanc, M., Geadah, D., Parent, D., Courteau, S., & Cardinal, J. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70076-4 · Cited by 231
The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients
Joynt, G. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.421 · Cited by 200
Self-citationNeurotoxicity induced by beta-lactam antibiotics: from bench to bedside
Chow, K. M., Hui, A. C., & Szeto, C. C. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0021-y · Cited by 183
Experience with a once-daily dosing program of aminoglycosides in critically ill patients
Buijk, S. L. C. E., Mouton, J. W., Gyssens, I. C., Verbrugh, H. A., & Bruining, H. A. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1313-7 · Cited by 162
Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis
Schliamser, S. E., Cars, O., & Norrby, S. R. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.4.405 · Cited by 158
Therapeutic Intervention and Targets for Sepsis
Rice, T. W., & Bernard, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104356 · Cited by 158
The Pathophysiology of Septic Shock
Nduka, O. O., & Parrillo, J. E. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.08.002 · Cited by 154
Continuous infusion of β-lactam antibiotics in severe infections: a review of its role
Roberts, J. A., Paratz, J., Paratz, E., Krueger, W. A., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.002 · Cited by 150
Self-citationPharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage
Böhler, J., Donauer, J., & Keller, F. (1999) · Kidney International · doi:10.1046/j.1523-1755.56.s.72.2.x · Cited by 140
Roberts, J. A., Boots, R. J., Rickard, C. M., Thomas, P., Quinn, J., Roberts, D. M., Richards, B., & Lipman, J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl478 · Cited by 138
Self-citationThe epidemiology of acute renal failure in the world
Uchino, S. (2006) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000247448.94252.5a · Cited by 137
Pharmacological Principles of Antibiotic Prescription in the Critically Ill
Pinder, M., Bellomo, R., & Lipman, J. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000203 · Cited by 135
Self-citationLi, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Self-citationMarik, P. E., Lipman, J., Kobilski, S., & Scribante, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.5.753 · Cited by 124
Self-citationVancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects
Golper, T. A., Noonan, H. M., Elzinga, L. W., Gilbert, D. N., Brummett, R. E., Anderson, J. L., & Bennett, W. M. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.74 · Cited by 121
Kielstein, J. T., Czock, D., Schoepke, T., Hafer, C., Bode‐Böger, S. M., Kuse, E. R., Keller, F., & Fliser, D. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000190243.88133.3f · Cited by 113
Continuous infusion ceftazidime in intensive care: a randomized controlled trial
Lipman, J., Gomersall, C. D., Gin, T., Joynt, G. M., & Young, R. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.2.309 · Cited by 107
Self-citationPharmacokinetics of continuous renal replacement therapy
Schetz, M., Ferdinande, P., den Berghe, G. V., Verwaest, C., & Lauwers, P. (1995) · Intensive Care Medicine · doi:10.1007/bf01700172 · Cited by 106
Bugge, J. F. (2001) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2001.450802.x · Cited by 106
Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin
Seddon, M., Wise, R. A., Gillett, A. P., & Livingston, R. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.18.2.240 · Cited by 105
Joy, M., Matzke, G. R., Frye, R. F., & Palevsky, P. M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9631848 · Cited by 104
Continuous infusion of beta-lactams
Mouton, J. W., & Vinks, A. A. T. M. M. (2007) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3282e2a98f · Cited by 103
Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration
Thalhammer, F., Schenk, P., Burgmann, H., Menyawi, I. E., Hollenstein, U., Rosenkranz, A. R., Sunder–Plassmann, G., Breyer, S., & Ratheiser, K. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2417 · Cited by 103
Fiaccadori, E., Maggiore, U., Rotelli, C., Giacosa, R., Parenti, E., Picetti, E., Sagripanti, S., Manini, P., Andreoli, R., & Cabassi, A. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000147687.06808.92 · Cited by 101
Schentag, J. J. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.6.426 · Cited by 100
Liver Dysfunction in Critical Illness
Hawker, F. (1991) · Anaesthesia and Intensive Care · doi:10.1177/0310057x9101900203 · Cited by 99
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling
Nicolau, D. P. (2003) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-003-0279-x · Cited by 99
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients
Kitzes‐Cohen, R., Farin, D., Piva, G., & Myttenaere-Bursztein, S. A. D. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00474-5 · Cited by 97
Cefepime Neurotoxicity: Case Report, Pharmacokinetic Considerations, and Literature Review
Lam, S., & Gomolin, I. H. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.8.1169 · Cited by 94
Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance
Macias, W. L., Mueller, B. A., & Scarim, S. K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.208 · Cited by 93
Pharmacokinetic Evaluation of Meropenem and Imipenem in Critically Ill Patients with Sepsis
Novelli, A., Adembri, C., Livi, P., Fallani, S., Mazzei, T., & Gaudio, A. R. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544050-00007 · Cited by 93
Intermittent bolus dosing of ceftazidime in critically ill patients
Young, R. P., Lipman, J., Gin, T., Gomersall, C. D., Joynt, G. M., & Oh, T. E. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.2.269 · Cited by 90
Self-citationChow, A. T., Fowler, C. L., Williams, R. R., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2122-2125.2001 · Cited by 90
Clinical Pharmacology of the Fluoroquinolones: Studies in Human Dynamic/Kinetic Models
Schentag, J. J. (2000) · Clinical Infectious Diseases · doi:10.1086/314059 · Cited by 87
Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients
Malone, R. S., Fish, D. N., Abraham, E., & Teitelbaum, I. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3148-3155.2001 · Cited by 87
Krueger, W. A., Schroeder, T. H., Hutchison, M., Hoffmann, E., Dieterich, H. ‐., Heininger, A., Erley, C., Wehrle, A., & Unertl, K. E. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2421 · Cited by 83
Fish, D. N., Teitelbaum, I., & Abraham, E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2421-2428.2005 · Cited by 80
Robatel, C., Decosterd, L. A., Biollaz, J., Eckert, P., Schaller, M., & Buclin, T. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003260286 · Cited by 78
Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy
Mueller, B. A., Pasko, D. A., & Sowinski, K. M. (2003) · Artificial Organs · doi:10.1046/j.1525-1594.2003.07283.x · Cited by 78
Mueller, S., Majcher-Peszynska, J., Hickstein, H., Francke, A., Pertschy, A., Schulz, M., Mundkowski, R. G., & Drewelow, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1557-1560.2002 · Cited by 77
Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution
Uchino, S., Cole, L., Morimatsu, H., Goldsmith, D., & Bellomo, R. (2002) · Intensive Care Medicine · doi:10.1007/s00134-002-1495-z · Cited by 74
Mueller, B. A., Scarim, S. K., & Macias, W. L. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)81089-4 · Cited by 74
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function
Capparelli, F. J., Díaz, M. F., Hlavnicka, A. A., Wainsztein, N. A., Leiguarda, R. C., & Castillo, M. I. (2005) · Neurology · doi:10.1212/01.wnl.0000187079.12413.6a · Cited by 73
Roosendaal, R., Bakker‐Woudenberg, I. A. J. M., Raffe, M. V. D. B.-V., Berg, J., & MICHEL, M. F. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963774 · Cited by 70
Bouman, C. S. C., van Kan, H. J. M., Koopmans, R. P., Korevaar, J. C., Schultz, M. J., & Vroom, M. B. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0397-x · Cited by 70
van der Auwera, P., Meunier, F., Sa, I., Kaufman, L., Derde, M. P., & Tulkens, P. M. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.640 · Cited by 68
Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?
Roberts, J. A., Hope, W. W., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.01.022 · Cited by 64
Self-citationArzuaga, A., Maynar, J., Rodríguez‐Gascón, A., Isla, A., Corral, E., Fonseca, F., Sánchez‐Izquierdo, J. Á., Rello, J., Canut, A., & Pedraz, J. L. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269796 · Cited by 64
Churchwell, M. D., & Mueller, B. A. (2009) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2008.00541.x · Cited by 63
Langgartner, J., Vasold, A., Glück, T., Reng, M., & Kees, F. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1034-7 · Cited by 63
Fantin, B., Farinotti, R., Thabaut, A., & Carbon, C. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.3.563 · Cited by 61
Isla, A., Maynar, J., Sánchez‐Izquierdo, J. Á., Rodríguez‐Gascón, A., Arzuaga, A., Corral, E., & Pedraz, J. L. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280583 · Cited by 61
Krueger, W. A., Neeser, G., Schuster, H., Schroeder, T. H., Hoffmann, E., Heininger, A., Dieterich, H., Forst, H., & Unertl, K. E. (2003) · Chemotherapy · doi:10.1159/000074527 · Cited by 59
Mariat, C., Venet, C., Jehl, F., Mwewa, S., Vesna, L., Diconne, É., Fonsale, N., Carricajo, A., Guyomarch, S., Vermesch, R., et al. (2006) · Critical Care · doi:10.1186/cc3993 · Cited by 57
Drusano, G. L. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.12part2.150s · Cited by 56
Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside
Rodvold, K. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.18.319s.33904 · Cited by 44
Vos, M. D., Vincent, H. H., & Yzerman, E. P. F. (1992) · Intensive Care Medicine · doi:10.1007/bf01706474 · Cited by 38
LaPlante, K. L., Rybak, M. J., Tsuji, B. T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-06 · Cited by 33
Lindsay, C. A., Bawdon, R. E., & Quigley, R. P. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb02978.x · Cited by 30
Ross, G. H., Wright, D. H., Hovde, L. B., Peterson, M. L., & Rotschafer, J. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2136-2140.2001 · Cited by 20
Pharmacokinetics of Antibiotics During Continuous Renal Replacement Therapy
Krueger, W. A., Schroeder, T. H., & Hansen, M. (2005) · Springer eBooks · doi:10.1007/0-387-26272-5_30 · Cited by 3
Research works printed but not linked: 57
- Rahman, 2002, Clin Med, 2, 108, 10.7861/clinmedicine.2-2-108 · doi:10.7861/clinmedicine.2-2-108
- Rangel-Frausto, 1995, JAMA, 273, 117, 10.1001/jama.1995.03520260039030 · DOI · Paper page
- Kubin, 2005, J Pharm Pract, 18, 109, 10.1177/0897190004273596 · doi:10.1177/0897190004273596
- Burgess, 1999, Chest, 115, 19S, 10.1378/chest.115.suppl_1.19S · doi:10.1378/chest.115.suppl_1.19s
- Tessier, 1999, Chemotherapy, 45, 284, 10.1159/000007198 · doi:10.1159/000007198
- Ronco, 2001, Nephrol Dial Transplant, 16, 67, 10.1093/ndt/16.suppl_5.67 · doi:10.1093/ndt/16.suppl_5.67
- Oda, 2002, Ther Apher, 6, 193, 10.1046/j.1526-0968.2002.00431.x · doi:10.1046/j.1526-0968.2002.00431.x
- Golper, 1998, Kidney Int Suppl, 66, S165
- Golper, 2001, Contrib Nephrol, &NA;, 349, 10.1159/000060103 · doi:10.1159/000060103
- Guenter, 2002, Pharmacotherapy, 22, 175, 10.1592/phco.22.3.175.33546 · doi:10.1592/phco.22.3.175.33546
- Malone, 2001, Antimicrob Agents Chemother, 45, 2949, 10.1128/AAC.45.10.2949-2954.2001 · doi:10.1128/aac.45.10.2949-2954.2001
- Hansen, 2001, Intensive Care Med, 27, 371, 10.1007/s001340000836 · doi:10.1007/s001340000836
- Traunmüller, 2001, J Antimicrob Chemother, 47, 229, 10.1093/jac/47.2.229 · doi:10.1093/jac/47.2.229
- Choi, 2004, Int J Antimicrob Agents, 24, 468
- Troyanov, 2003, Nephrol Dial Transplant, 18, 961, 10.1093/ndt/gfg055 · doi:10.1093/ndt/gfg055
- Lipman, 1998, Antimicrob Agents Chemother, 42, 2235, 10.1128/AAC.42.9.2235 · doi:10.1128/aac.42.9.2235
- Wallis, 2001, Intensive Care Med, 27, 665, 10.1007/s001340100857 · doi:10.1007/s001340100857
- Giles, 2000, Crit Care Med, 28, 632, 10.1097/00003246-200003000-00005 · doi:10.1097/00003246-200003000-00005
- Ververs, 2000, Crit Care Med, 28, 3412, 10.1097/00003246-200010000-00006 · doi:10.1097/00003246-200010000-00006
- Isla, 2007, Chemotherapy, 53, 194, 10.1159/000100864 · doi:10.1159/000100864
- Hassan, 1987, Antimicrob Agents Chemother, 31, 1855, 10.1128/AAC.31.11.1855 · doi:10.1128/aac.31.11.1855
- Jones, 1997, J Antimicrob Chemother, 40, 121, 10.1093/jac/40.1.121 · doi:10.1093/jac/40.1.121
- Tian, 2008, Antimicrob Agents Chemother, 52, 1009, 10.1128/AAC.00858-07 · doi:10.1128/aac.00858-07
- Meyers, 1983, Antimicrob Agents Chemother, 24, 812, 10.1128/AAC.24.5.812 · doi:10.1128/aac.24.5.812
- Gonzalez, 1985, Clin Pharmacol Ther, 37, 633, 10.1038/clpt.1985.102 · doi:10.1038/clpt.1985.102
- de Pont, 2007, Curr Opin Crit Care, 13, 668, 10.1097/MCC.0b013e3282f0febd · doi:10.1097/mcc.0b013e3282f0febd
- Tian, 2008, Artif Organs, 32, 81, 10.1111/j.1525-1594.2007.00460.x · doi:10.1111/j.1525-1594.2007.00460.x
- Leone, 2004, Antimicrob Agents Chemother, 48, 638, 10.1128/AAC.48.2.638-640.2004 · doi:10.1128/aac.48.2.638-640.2004
- Rubinstein, 2002, J Antimicrob Chemother, 49, 593, 10.1093/jac/49.4.593 · doi:10.1093/jac/49.4.593
- Capellier, 1998, Crit Care Med, 26, 88, 10.1097/00003246-199801000-00021 · doi:10.1097/00003246-199801000-00021
- Keller, 1995, Clin Nephrol, 43, S20
- Meyer, 2003, Kidney Blood Press Res, 26, 135, 10.1159/000070997 · doi:10.1159/000070997
- Davies, 1991, Nephrol Dial Transplant, 6, 971, 10.1093/ndt/6.12.971 · doi:10.1093/ndt/6.12.971
- Weiss, 1988, Clin Nephrol, 30, 282
- Traunmuller, 2002, J Antimicrob Chemother, 49, 129, 10.1093/jac/49.1.129 · doi:10.1093/jac/49.1.129
- Matzke, 2000, Antimicrob Agents Chemother, 44, 1639, 10.1128/AAC.44.6.1639-1644.2000 · doi:10.1128/aac.44.6.1639-1644.2000
- Kroh, 1996, J Clin Pharmacol, 36, 1114, 10.1002/j.1552-4604.1996.tb04164.x · doi:10.1002/j.1552-4604.1996.tb04164.x
- Isla, 2005, Clin Ther, 27, 599, 10.1016/j.clinthera.2005.05.004 · doi:10.1016/j.clinthera.2005.05.004
- Keller, 1989, Nephrol Dial Transplant, 4, 640
- Tegeder, 1997, Antimicrob Agents Chemother, 41, 2640, 10.1128/AAC.41.12.2640 · doi:10.1128/aac.41.12.2640
- Hashimoto, 1997, ASAIO J, 43, 84
- Tegeder, 1999, Clin Pharmacol Ther, 65, 50, 10.1016/S0009-9236(99)70121-9 · doi:10.1016/s0009-9236(99)70121-9
- Fuhrmann, 2004, J Antimicrob Chemother, 54, 780, 10.1093/jac/dkh421 · doi:10.1093/jac/dkh421
- Barrie, 1992, Intensive Care Med, 18, 437, 10.1007/BF01694350 · doi:10.1007/bf01694350
- DelDot, 2004, Br J Clin Pharmacol, 58, 259, 10.1111/j.1365-2125.2004.02143.x · doi:10.1111/j.1365-2125.2004.02143.x
- Boereboom, 1999, Intensive Care Med, 25, 1100, 10.1007/s001340051018 · doi:10.1007/s001340051018
- Yagasaki, 2003, Intensive Care Med, 29, 2094, 10.1007/s00134-003-1914-9 · doi:10.1007/s00134-003-1914-9
- Pea, 2001, Drug Monit, 23, 587, 10.1097/00007691-200110000-00013 · doi:10.1097/00007691-200110000-00013
- Wolter, 1994, Eur J Clin Pharmacol, 46, 179, 10.1007/BF00199886 · doi:10.1007/bf00199886
- Zarowitz, 1986, J Clin Pharmacol, 26, 686, 10.1002/j.1552-4604.1986.tb02973.x · doi:10.1002/j.1552-4604.1986.tb02973.x
- Ernest, 1992, Crit Care Med, 20, 586, 10.1097/00003246-199205000-00007 · doi:10.1097/00003246-199205000-00007
- Syka, 2005, J Clin Pharmacol, 45, 477, 10.1177/0091270004273949 · doi:10.1177/0091270004273949
- Robert, 1991, Crit Care Med, 19, 588, 10.1097/00003246-199104000-00029 · doi:10.1097/00003246-199104000-00029
- Moon, 2006, Korean J Nephrol, 25, 595
- Pea, 2004, Am J Kidney Dis, 44, 1097, 10.1053/j.ajkd.2004.08.032 · doi:10.1053/j.ajkd.2004.08.032
- Meyer, 2005, J Antimicrob Chemother, 56, 172, 10.1093/jac/dki133 · doi:10.1093/jac/dki133
- Churchwell, 2006, Blood Purif, 24, 548, 10.1159/000097078 · doi:10.1159/000097078
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationThe Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Metadata
- Authors
- Choi, G., Gomersall, C. D., Tian, Q., Joynt, G. M., Freebairn, R., & Lipman, J.
- Venue
- Critical Care Medicine
- Published
- 2009-07
- Volume
- 37
- Issue
- 7
- Pages
- 2268-2282
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2017487363
- Cited by
- 334
- References
- 95
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.